Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Sarcoma × futibatinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

Radiotherapy 9 Nivolumab 9 pembrolizumab 8 Magnetic Resonance Spectroscopy 8 Doxorubicin 8 Specimen Handling 7 X-Rays 6 Cyclophosphamide 6 Biopsy 6 Phantoms, Imaging 5 Ipilimumab 5 talimogene laherparepvec 4 Radiation 4 Nuclear Medicine Department, Hospital 4 selpercatinib 3 pazopanib 3 palbociclib 3 cabozantinib 3 Sirolimus 3 Ifosfamide 3 Bevacizumab 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 olaparib 2 liposomal doxorubicin 2 larotrectinib 2 ivosidenib 2 entrectinib 2 ensartinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡